Xinyu Yang

Guanyu Hu, Jie Wei, Siyang Song et al.

The objective of the Multiple Appropriate Facial Reaction Generation (MAFRG) task is to produce contextually appropriate and diverse listener facial behavioural responses based on the multimodal behavioural data of the conversational partner (i.e., the speaker). Current methodologies typically assume continuous availability of speech and facial modality data, neglecting real-world scenarios where these data may be intermittently unavailable, which often results in model failures. Furthermore, despite utilising advanced deep learning models to extract information from the speaker's multimodal inputs, these models fail to adequately leverage the speaker's emotional context, which is vital for eliciting appropriate facial reactions from human listeners. To address these limitations, we propose an Emotion-aware Modality Compensatory (EMC) framework. This versatile solution can be seamlessly integrated into existing models, thereby preserving their advantages while significantly enhancing performance and robustness in scenarios with missing modalities. Our framework ensures resilience when faced with missing modality data through the Compensatory Modality Alignment (CMA) module. It also generates more appropriate emotion-aware reactions via the Emotion-aware Attention (EA) module, which incorporates the speaker's emotional information throughout the entire encoding and decoding process. Experimental results demonstrate that our framework improves the appropriateness metric FRCorr by an average of 57.2\% compared to the original model structure. In scenarios where speech modality data is missing, the performance of appropriate generation shows an improvement, and when facial data is missing, it only exhibits minimal degradation.

Tengfei Ma, Xuan Lin, Tianle Li et al.

Large Language Models (LLMs) have recently demonstrated remarkable performance in general tasks across various fields. However, their effectiveness within specific domains such as drug development remains challenges. To solve these challenges, we introduce \textbf{Y-Mol}, forming a well-established LLM paradigm for the flow of drug development. Y-Mol is a multiscale biomedical knowledge-guided LLM designed to accomplish tasks across lead compound discovery, pre-clinic, and clinic prediction. By integrating millions of multiscale biomedical knowledge and using LLaMA2 as the base LLM, Y-Mol augments the reasoning capability in the biomedical domain by learning from a corpus of publications, knowledge graphs, and expert-designed synthetic data. The capability is further enriched with three types of drug-oriented instructions: description-based prompts from processed publications, semantic-based prompts for extracting associations from knowledge graphs, and template-based prompts for understanding expert knowledge from biomedical tools. Besides, Y-Mol offers a set of LLM paradigms that can autonomously execute the downstream tasks across the entire process of drug development, including virtual screening, drug design, pharmacological properties prediction, and drug-related interaction prediction. Our extensive evaluations of various biomedical sources demonstrate that Y-Mol significantly outperforms general-purpose LLMs in discovering lead compounds, predicting molecular properties, and identifying drug interaction events.